Sino Biological, Inc. (Shenzhen Stock Exchange: 301047.SZ) announced the launch of its XPressMAX™ Cell-Free Protein Synthesis Kit (Cat#: CFKIT02), a novel tool designed to accelerate AI-powered high-throughput screening for antibody drug discovery. The kit uses advanced cell-free protein synthesis technology to produce target proteins and antibodies in vitro in as little as 3 hours, bypassing the limitations of traditional cell-based expression systems.
According to the company, the XPressMAX™ kit is based on an E. coli lysate fully supplemented with essential transcription and translation components, allowing direct protein synthesis from plasmid or PCR templates. It is specifically designed for antibody drug discovery, enabling rapid expression and validation of VHH, scFv, Fab, and miniproteins. Sino Biological has leveraged this technology to establish a high-throughput cell-free expression platform that validates over 2,000 scFv/VHH molecules in 3-4 weeks, matching the rapid iteration speed of AI algorithms.
Key highlights of the kit include ultra-fast synthesis completion in 3 hours, a greater than 99% success rate, and support for complex disulfide bonding without additional enhancers, ensuring native folding and bioactivity. This capability is critical for AI-driven drug discovery, where large libraries of antibody candidates must be screened quickly.
Dr. Rob Burgess, Chief Business Officer at Sino Biological US, Inc., stated, "Our XPressMAX™ is a significant advancement in research tools and reagents for next-generation therapeutic discovery. By combining rapid, reliable protein expression with intelligent screening, we are helping our partners compress antibody discovery timelines without compromising quality." Dr. Jie Zhang, Sino Biological’s General Manager, added, "AI is revolutionizing antibody screening, but it demands expression systems that can match its speed and throughput. XPressMAX™ achieves rapid, high-success expression of challenging proteins in as little as 3 hours."
The implications of this launch are substantial for the pharmaceutical and biotechnology industries. By enabling faster validation of AI-predicted antibody candidates, the kit could significantly reduce the time and cost of early-stage drug development. This is particularly important as AI models generate increasingly large numbers of potential hits that need experimental confirmation. The ability to synthesize proteins in hours rather than days or weeks could accelerate the entire discovery pipeline, potentially bringing new therapies to patients faster.
Researchers can explore more about XPressMAX™ at Sino Biological's product page or request a free sample through this form. The company also provides additional information on its cell-free expression platform at this link.
